0
  • Notifications
  • No notifications yet

  • View All Notifications
ChemDmart
Chemxpert Database
  • About
    • About
    • Leadership
    • Advisory Board
  • Products
    • ChemProtel - Product Intelligence
    • CompFolio - One Company Profile
    • CompGroupe - Group Company Profile
    • ChemScape - Data Landscape
    • ChemDmart - E-Market Place
    • DataIntel - Data Analytics/Trends
    • DataFeed - Data News/Feed
    • CompShow- Company Showcase
  • Sources
  • Subscription
  • User Guide
  • Contact
  • Book Demo Log In
  1. Home
  2. All News
  3. Sandoz Completes Acquisition Of Antifungal Agent Mycamine From Astellas
News Feed
course image
  • 29 Aug 2023
  • Admin
  • News Article

Sandoz completes acquisition of antifungal agent Mycamine from Astellas

Sandoz, a global leader in generic and biosimilar medicines, has successfully completed the acquisition of worldwide brand rights for leading systemic antifungal agent Mycamine (micafungin sodium, Funguard in Japan) from Astellas.

Through this acquisition of the leading global echinocandin, one of three major antifungal classes, Sandoz significantly reinforces its global hospital offering and leading anti-infectives portfolio.

Astellas reported Mycamine sales of JPY 14.2 billion (USD 105 million) for the year ending March 31, 2023. The announcement comes after Sandoz successfully completed the acquisition of GSK’s global cephalosporins portfolio in October 2021.

Sandoz CEO Richard Saynor said: “This is another sign of our commitment at Sandoz to driving responsible access to critical antimicrobial medicines. We are both investing in our production network and selectively building out our leading portfolio in this field to ensure that we can continue to offer patients around the world the right medicine at the right time.”

Mycamine has a global patient base of well over two million. It is a therapy of choice in hospitals and intensive care units worldwide, a proven prophylactic in haematology and oncology patients, and widely used in organ transplants.

It is indicated for treatment of invasive candidiasis and esophageal candidiasis, which are currently both on the rise with a higher occurrence of associated hospital outbreaks, as well as prevention of candida and aspergillus infections in patients undergoing hematopoietic stem cell transplantation.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!

Categories

image
Product Related Updates
image
Certificates/Accreditation
image
Approval/Launch
image
Clinical Trial Update
image
Licensing/Partnering/Collaboration Deal
image
ODD/BTA/FTA Status
image
Merger/Acquisition
image
Warning/Recalls

Lifescience Intellipedia Pvt. Ltd.

C-89, Sector-65 Noida-U.P. 201301 (India)
Toll-Free: 18004190155
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com

USEFUL LINKS

  • Home
  • Privacy Policy
  • Terms & Conditions
  • Terms Of Use
  • Refund Policy
  • Blogs

OUR PRODUCTS

  • ChemProtel - Product Intelligence
  • CompFolio - One Company Profile
  • CompGroupe - Group Company Profile
  • ChemScape - Data Landscape
  • ChemDmart - E-Market Place
  • DataIntel - Data Analytics/Trends
  • DataFeed - Data News/Feed
  • CompShow- Company Showcase

LOCATION

© Copyright Lifescience Intellipedia Pvt. Ltd.. All Rights Reserved

Fill The Form